Us Bancorp \De\ Cure Vac N.V. Transaction History

Us Bancorp \De\

$77.3 Billion
Q3 2024

A detailed history of Us Bancorp \De\ transactions in Cure Vac N.V. stock. As of the latest transaction made, Us Bancorp \De\ holds 2,576 shares of CVAC stock, worth $6,414. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,576

Previous 2,794 7.8%

Holding current value

$6,414

Previous $9,000 22.22%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 28, 2024	SELL	$2.74 - $3.79 $597 - $826	-218 Reduced 7.8%	2,576 $7,000
Q2 2024 Aug 06, 2024	BUY	$2.31 - $4.99 $422 - $913	183 Added 7.01%	2,794 $9,000
Q1 2024 May 07, 2024	SELL	$2.94 - $4.34 $4,218 - $6,227	-1,435 Reduced 35.47%	2,611 $7,000
Q4 2023 Feb 09, 2024	BUY	$3.96 - $6.41 $3,722 - $6,025	940 Added 30.26%	4,046 $17,000
Q3 2023 Nov 03, 2023	SELL	$6.5 - $10.77 $6,051 - $10,026	-931 Reduced 23.06%	3,106 $21,000
Q2 2023 Aug 09, 2023	BUY	$6.69 - $12.25 $2,301 - $4,214	344 Added 9.31%	4,037 $42,000
Q1 2023 May 09, 2023	BUY	$6.38 - $12.5 $7,585 - $14,862	1,189 Added 47.48%	3,693 $25,000
Q4 2022 Feb 13, 2023	BUY	$5.75 - $8.5 $8,239 - $12,180	1,433 Added 133.8%	2,504 $15,000
Q3 2022 Oct 27, 2022	SELL	$7.48 - $15.24 $24,930 - $50,794	-3,333 Reduced 75.68%	1,071 $9,000
Q2 2022 Aug 01, 2022	SELL	$13.18 - $19.41 $49,016 - $72,185	-3,719 Reduced 45.78%	4,404 $60,000
Q1 2022 May 11, 2022	BUY	$14.73 - $35.25 $9,795 - $23,441	665 Added 8.92%	8,123 $159,000
Q4 2021 Feb 11, 2022	BUY	$33.72 - $48.22 $72,498 - $103,673	2,150 Added 40.5%	7,458 $256,000
Q3 2021 Nov 10, 2021	BUY	$49.26 - $74.5 $261,472 - $395,446	5,308 New	5,308 $289,000

Others Institutions Holding CVAC

# of Institutions

Shares Held

12.3M

Call Options Held

164K

Put Options Held

117K

View Full List

About CureVac N.V.

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $467M
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

More about CVAC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account